Key Drivers
- Gross Margin
- Cash Burn
- Balance Sheet
AIAI Summary
IBRX has shifted from a speculative biotech story to an early commercial growth name with real Anktiva revenue traction, but the stock has likely outrun fundamentals as persistent losses, negative cash flow, heavy debt, and litigation mean investors should wait for repeatable sales growth and operating leverage before assuming the rerating is sustainable.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Burn
- •Balance Sheet
IBRX shows strong gross margins and liquidity, but persistent losses, negative cash flow, rising debt, and deeply negative equity keep the risk profile elevated.
Price Behavior
Key Price Behavior Insights:
- •Breakout above
- •Higher highs
- •Pullback risk
IBRX is in a strong short-term uptrend after breaking above the $8.76-$8.80 consolidation zone, but it is extended and must hold $9.20 to sustain the move.
Fast, uneven rally from $7.18 to $9.44 with sharp swings and a recent breakout from consolidation
Sentiment & News
Key News Insights:
- •Strong price jump
- •Above-average volume
- •Revision caution
ImmunityBio surged 11.8% on above-average volume, but softer earnings-revision trends suggest the rally may not have much near-term follow-through.
This move highlights strong short-term investor interest in IBRX, but the lack of supportive estimate upgrades limits confidence in sustained upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings